Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
Varenicline Pharmacological and Expectancy Effects on Medication Adherence (Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The current proposal will utilize the double-blind balanced placebo design to differentiate expectancies versus pharmacologic mechanisms of varenicline administered to varenicline naïve smokers seeking treatment (N = 80) for two-weeks. Race block randomization (controlling for baseline expectancies) will be used to randomize participants. The double-blind balanced placebo design includes a cross-balanced medication administration (active medication v. placebo) and instructional set (told truth v. deception) resulting in four groups of smokers seeking treatment (n = 20 for each): (1) told therapeutic dose (TD) medication + received TD medication; (2) told TD medication + received placebo; (3) told low dose (LD) medication+ received TD dose medication; (4) told LD medication + received placebo. Participants will be told they received low dose (rather than placebo) due to concerns that participants will not take a medication that they believe to be a placebo. Ecological momentary assessments (EMA) in the form of Daily Dairies delivered via smartphone will assess real-time side effects, withdrawal symptoms, cigarettes smoked, medication use, and reasons for medication non-adherence. The current proposal will test the following specific aims:
Specific Aim 1: Examine the main effects of instructional set and pharmacology. Hypothesis 1: Main effects for TD instructional set and active medication administration will result in reduced medication adherence compared with LD instructional set and placebo medication.
Specific Aim 2: Examine the interaction between instructional set and pharmacology. Hypothesis 2: There will be a synergistic (i.e., non-additive) effect between instructional set and pharmacology. Specifically, those assigned to the TD instructional set and active medication group will result in a 50% discontinuation compared to a 20% discontinuation in the TD instructional set and placebo medication group.
Exploratory Aim: Evaluate moderators of pharmacology and expectancy effects on medication adherence. First, we will conduct exploratory examination of baseline medication expectancies moderating the relationship between pharmacology and medication adherence. Second, we will conduct an exploratory evaluation of potential moderators (e.g., gender and race) of pharmacology and baseline medication expectancy.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Smoking at least 5 cigarettes per day (cpd) for the past year
- A carbon monoxide (CO) >10ppm
- English speaking
- Must own a cellphone with SMS text capacity with Internet access OR daily use of email
- Must be varenicline naïve
- Express a desire to quit smoking
Exclusion Criteria:
- Living in a restricted environment (e.g., prison or jail facility, etc.)
- Pregnant or nursing
- Currently enrolled in a smoking cessation treatment program, using NRT products, or prescribed bupropion or varenicline
- Known allergy to varenicline
- History of kidney disease, dialysis or known kidney impairment
- Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process (individuals stable on psychiatric medications will be included)
- Daily or exclusive use of other tobacco products
- Current suicidal or homicidal ideation or a suicidal attempt within the past 12 months
- History of stroke, heart attack, or seizures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Therapeutic Dose Truth
told therapeutic dose medication + received therapeutic dose medication
|
Participants will be provided varenicline medication
|
|
Placebo Comparator: Therapeutic Dose Deception
told therapeutic dose medication + received placebo
|
Participants will be provided placebo medication
|
|
Active Comparator: Low Dose Vareniclince Deception
told low dose medication + received therapeutic dose medication
|
Participants will be provided varenicline medication
|
|
Placebo Comparator: Low Dose Placebo Deception
told low dose medication + received placebo
|
Participants will be provided placebo medication
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication Adherence
Time Frame: Days 1 - 13
|
Self-reported medication adherence measured through a single item assessing medication compliance.
The item is answered as "yes" (scored as 1) or "no" (scored as 0).
This measure combines all responses from Day 1 through Day 13 of this study to provide a total measure of medication adherence ranging from 0% (missed all doses) to 100% (took every dose as prescribed).
Higher scores indicate better outcomes (i.e., better adherence to medication).
|
Days 1 - 13
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication Expectancies
Time Frame: Baseline and Day 14
|
Medication expectancies will be measured through the Beliefs and Attitudes about Varenicline (BAV) scale which is a 6-item questionnaire adapted to assess varenicline expectancies.
This measure is rated on a scale from 1 (not at all) to 5 (extremely).
The measure has a minimum score of 6 and a maximum score of 30.
Higher scores indicating better outcomes (i.e., stronger positive beliefs about using varenicline).
|
Baseline and Day 14
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Side Effects
Time Frame: Day 14
|
A 30-item self-report measure of the presence (or not) of symptoms commonly associated with varenicline side effects and nicotine withdrawal.
Items are rated as "No" (scored as 0) or "Yes" (scored as 1).
A total score was calculated to reflect the total number of reported side effects.
This measure has a minimum score of 0 and a maximum score of 30.
Higher scores indicate worse outcomes (i.e., greater frequency of experienced side effects).
|
Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-300001404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.